Screening for Dementia: Recommendations and Rationale: United States Preventive Services Task Force
United States Preventive Services Task Force
guidelines, medicine, prevention, screening, u.s. preventive services task force
United States Preventive Services Task Force. Screening for Dementia: Recommendations and Rationale: United States Preventive Services Task Force. The Internet Journal of Mental Health. 2003 Volume 2 Number 1.
Summary Of Recommendation
The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against routine screening for dementia in older adults.
The Mini-Mental Status Examination (MMSE) is the best-studied instrument for screening for cognitive impairment. When the MMSE is used to screen unselected patients, the predictive value of a positive result is only fair. The accuracy of the MMSE depends upon a person's age and educational level: using an arbitrary cut-point may potentially lead to more false-positives among older people with lower educational levels, and more false-negatives among younger people with higher educational levels. Tests that assess functional limitations rather than cognitive impairment, such as the Functional Activities Questionnaire (FAQ), can detect dementia with sensitivity and specificity comparable to that of the MMSE.
Early recognition of cognitive impairment, in addition to helping make diagnostic and treatment decisions, allows clinicians to anticipate problems the patients may have in understanding and adhering to recommended therapy. This information may also be useful to the patient's caregiver(s) and family member(s) in helping to anticipate and plan for future problems that may develop as a result of progression of cognitive impairment.
Although current evidence does not support routine screening of patients in whom cognitive impairment is not otherwise suspected, clinicians should assess cognitive function whenever cognitive impairment or deterioration is suspected, based on direct observation, patient report, or concerns raised by family members, friends, or caretakers.
Epidemiology and Clinical Consequences
Dementia is defined as an acquired syndrome of decline in memory and at least one other cognitive domain such as language, visuo-spatial, or executive function sufficient to interfere with social or occupational functioning in an alert person.4 The USPSTF did not review evidence on screening individuals with “mild cognitive impairment,” a condition not associated with functional impairment but that sometimes progresses to dementia.5
Alzheimer's disease and cerebrovascular ischemia (vascular dementia) are the two most common causes of dementia. Between 60% and 70% of individuals with dementia have Alzheimer's disease; about 20% to 30% have either vascular dementia or a combination of vascular dementia and Alzheimer's disease.3 Dementia causes a high burden of suffering for patients and their families. For patients, it increases dependency and complicates other medical conditions. For families it can lead to anxiety and depression, and may increase the time needed to care for loved ones. The annual economic cost of dementia is estimated to be $100 billion.6
Age is the strongest risk factor for dementia: 3% to 11% of people older than 65, and 25% to 47% of those older than 85 have dementia. 2 First degree relatives of patients with Alzheimer's disease have a cumulative lifetime risk of 39%, approximately twice the risk of Alzheimer's disease in the general population.7 Some genetic mutations have been associated with Alzheimer's disease: about 20% to 30% of the general population and 45% to 60% of people with late-onset Alzheimer's disease have the apolipoprotein E-4 (APOE- 4) gene.8 Cardiovascular risk factors such as hypertension are associated with an increased risk of both Alzheimer's disease and vascular dementia.9,10,11
Accuracy and Reliability of Screening Tests
Screening tests used for dementia are either direct cognitive tests of patients or functional assessments using patients and others as informants. Most screening tests have been evaluated in studies with small sample sizes, and the populations of patients on whom screening instruments have been tested have varied greatly, making it difficult to determine the overall performance of screening tests for dementia. The best evidence is available for a cognitive test – the Mini-Mental Status Examination (MMSE) – from studies in primary care settings that used standardized diagnostic instruments (eg, the DSM-IV) as a “gold standard.” Depending upon the cutpoint used for an abnormal test, the sensitivity of MMSE for dementia ranges from 71% to 92%, and the specificity ranges from 56% to 96%.12,13,14,15,16,17,18,19 The predictive value of a positive test, in a population with 10% prevalence of dementia, may range from 15% to 72%.2 A drawback of MMSE is that its accuracy depends upon age, education, and ethnicity of the individual; it is most accurate for whites with at least a high school education. 2 Other cognitive screening tests, such as the Short Portable Mental Status Questionnaire, Clock Drawing Test, Modified MMSE, Mini-Cog, Hopkins Verbal Learning Test, and the 7-minute screen are promising, but have not been adequately evaluated in primary care settings. 2
Some informant-based functional tests, such as the Functional Activities Questionnaire (FAQ), the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), and the Instrumental Activities of Daily Living (IADL) Questionnaire, have also been tested. 3,12,17 The sensitivity and specificity of FAQ is reported to be 90%.12 The functional test instruments offer the advantages of “everyday relevance,” acceptability by subjects, adaptability to various types of patients, administrative ease, longitudinal perspective, and cross-cultural portability. The primary limitations of these tests are that not all patients have caregivers and that some functions (eg, cognition) are not tested. Most importantly, few methodologically sound studies regarding the accuracy of these questionnaires in primary care settings have been completed.
Testing for genetic mutations may eventually prove useful in screening individuals at risk for Alzheimer's disease. There are, however, limited population-based data regarding the absolute risk of dementia among individuals having a positive genetic test. Thus the potential benefits and harms of testing for an individual patient are uncertain. Finally, the ethical issues in genetic testing for dementia are unresolved.
Effectiveness of Early Detection
The USPSTF found no direct evidence examining the effectiveness of screening for dementia in primary care settings in which the clinical outcomes of a population of patients who are screened, diagnosed, and treated are compared with outcomes in a population receiving usual care. To assess possible benefits of detecting undiagnosed dementia, the USPSTF examined trials of therapies aimed at improving the cognitive function of patients with dementia. The natural history of Alzheimer's disease is of progressive decline in cognitive function, thus an “improvement” from an intervention means a slowing of the rate of decline.
Several studies have examined non-pharmacological interventions (eg, behavioral training, caregiver education, and supportive services), directed either at the patient or the caregiver, in improving patient or caregiver outcomes. A systematic review and a RCT examined interventions directed at caregivers of people with mild to moderate dementia and found no significant differences in caregiver burden between intervention and control groups.40,41 Four well-conducted RCTs testing multi-component interventions yielded positive benefits. Two produced modest benefits in caregiver outcomes,42,43 and 2 studies found that intensive, comprehensive caregiver interventions enabled the caregivers to maintain affected persons at home for a 11 to 19 months longer compared with those who did not receive the intervention.44,45 None of these studies demonstrated a significant impact on patient outcomes. Subjects in these studies had clinically diagnosed disease and needed caregivers. The extent to which such interventions would be useful to caregivers of people with milder degrees of dementia (as is likely to occur in those detected by screening) is unclear. Additionally, these studies used multi-component interventions, making it difficult to assess the impact of individual components. These factors make it difficult to generalize the potential benefits of these interventions to patients who would be detected by routine screening in primary care settings.
Early detection and treatment of dementia due to a reversible cause is a potential benefit of screening for dementia. The USPSTF reviewed evidence to assess the prevalence of dementias due to conditions such as vitamin B12 deficiency, thyroid disease, neurosyphilis, normal pressure hydrocephalus, or sleep apnea. No study provided information applicable to a screened population; the data from studies done in specialty clinics indicate that only 1.5% of cases could be classified as fully reversible dementia. 3
Potential Adverse Effects of Screening
The harms of dementia screening have not been systematically examined. Both false-positive and true positive results could have adverse psychological effects on patients, but the USPSTF found few studies that address these outcomes. In one study of patients undergoing a detailed assessment of mental function, fewer than 5% found the screening itself distressing, intrusive or depressing46; no studies were found of patient attitudes towards more limited tests of cognitive function such as the MMSE. Once screening identifies an individual with low cognitive function, clinicians have some concern over the disclosure of information to patients regarding their dementia status. The USPSTF found several case reports of suicide in patients with newly diagnosed Alzheimer's disease, 47,48 but found no evidence of this potential adverse event in screening studies. A diagnosis of dementia could have effects on a patient's autonomy, but the USPSTF found no evidence supporting this concern. More established risks of receiving the diagnosis of dementia are difficulty obtaining medical or life insurance, or acceptance into assisted-living communities.
The most commonly reported adverse effects in patients taking cholinesterase inhibitors are nausea, vomiting, weight loss, and diarrhea. Tacrine also has significant gastrointestinal and hepatic adverse effects. The dropout rates in RCTs of cholinesterase inhibitors were higher in the groups taking cholinesterase inhibitors than in those taking placebo. In RCTs of other drugs, dropout rates did not differ significantly between those who took gingko biloba, selegiline, or vitamin E and those who took placebos.
Recommendations Of Others
There are no formal recommendations for routine screening for dementia. The American Academy of Neurology and the Canadian Task Force on Preventive Health Care concluded that there is insufficient evidence to recommend cognitive screening of asymptomatic individuals.49,50 The American Medical Association and the American Academy of Family Physicians recommend that physicians be alert for cognitive and functional decline in elderly patients for recognition of dementia in its early stages.51,52
Corresponding Author: Corresponding Author: Alfred O. Berg, MD, MPH, Chair, U.S. Preventive Services Task Force, c/o Center for Practice and Technology Assessment, Agency for Healthcare Research and Quality, 6010 Executive Boulevard, Suite 300, Rockville, MD 20852. (301) 594-4016, fax (301) 594 –4027, E-mail: email@example.com.
Members of the U.S. Preventive Services Task Force are Alfred O. Berg, MD, MPH, Chair, USPSTF (Professor and Chair, Department of Family Medicine, University of Washington, Seattle, WA); Janet D. Allan, PhD, RN, Vice-chair, USPSTF (Dean, School of Nursing, University of Maryland Baltimore, Baltimore, MD); Paul Frame, MD (Tri-County Family Medicine, Cohocton, NY, and Clinical Professor of Family Medicine, University of Rochester, Rochester, NY); Charles J. Homer, MD, MPH* (Executive Director, National Initiative for Children's Healthcare Quality, Boston, MA); Mark S. Johnson, MD, MPH (Chair, Department of Family Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ); Jonathan D. Klein, MD, MPH (Associate Professor, Department of Pediatrics, University of Rochester School of Medicine, Rochester, NY); Tracy A. Lieu, MD, MPH* (Associate Professor, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA); Cynthia D. Mulrow, MD, MSc* (Clinical Professor and Director, Department of Medicine, University of Texas Health Science Center, San Antonio, TX); C. Tracy Orleans, PhD (Senior Scientist and Senior Program Officer, The Robert Wood Johnson Foundation, Princeton, NJ); Jeffrey F. Peipert, MD, MPH* (Director of Research, Women and Infants' Hospital, Providence, RI); Nola J. Pender, PhD, RN* (Professor Emeritus, University of Michigan, Ann Arbor, MI); Albert L. Siu, MD, MSPH (Professor of Medicine, Chief of Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY); Steven M. Teutsch, MD, MPH (Senior Director, Outcomes Research and Management, Merck & Company, Inc., West Point, PA); Carolyn Westhoff, MD, MSc (Professor of Obstetrics and Gynecology and Professor of Public Health, Columbia University, New York, NY); and Steven H. Woolf, MD, MPH (Professor, Department of Family Practice and Department of Preventive and Community Medicine, Fairfax, VA).
*Member of the USPSTF at the time this recommendation was finalized.
The USPSTF recommendations are independent of the U.S. government. They do not represent the views of the Agency for Healthcare Research and Quality (AHRQ), the U.S. Department of Health and Human Services, or the U.S. Public Health Service.
Find more information about
Agency for Healthcare Research and Quality http://www.ahrq.gov/